Search | Médecins Sans Frontières Access Campaign

59 results found
There is 1 active filter
Clear all filters
generic medicines

59 results found

Issue brief |

18 September 2019

Making the Switch

Saving more lives with optimal treatment for drug-resistant TB

Tags Tuberculosis drug-resistant TBtuberculosis moxifloxacinlinezolidbedaquilinedelamanid access to medicinesdiagnostic testsgeneric medicinesinnovationresearch and development (R&D)voluntary licence Union Conference on Lung HealthTB AllianceJohnson & JohnsonOtsuka DRTB Drugs Under the Microscope

Press release |

01 July 2019

MSF update on 26th round of RCEP negotiations in Melbourne, Australia

While we welcome the recent withdrawal of harmful provisions from the IP chapter of RCEP, namely patent term extensions and data exclusivity, Japan’s strong push for elevated IP enforcement measures continues to be a matter of grave ...

Tags Intellectual property and trade generic medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) India

Statement |

30 November 2018

Tribute to Dr Amit Sengupta

Tags HIV/AIDS access to medicinesgeneric medicinesintellectual property & trade

Issue brief |

22 October 2018

DR-TB Drugs Under the Microscope, 5th Edition

The 5 th edition of “DR-TB Drugs Under the Microscope” chronicles the changing landscape of available treatments for DR-TB, outlines the key barriers to accessing the most effective treatments, and makes recommendations for action that ...

In March 2017, organisations from 17 European countries filed an opposition to Gilead Science's patent on the highly effective hepatitis C drug sofosbuvir. On 13th and 14th of September 2018, the hearing took e place before the European Patent Office in Munich.

Press release |

13 September 2018

MSF response to ruling in Gilead sofosbuvir patent hearing at European Patent Office

Tags Hepatitis C hepatitis C sofosbuvir generic medicinesintellectual property & trade

First set of free Hepatitis C medicines Sofosbuvir and Daclatasvir provided by Delhi Govt. run GB Pant hospital. Photograph by Garvit Nangia

Press release |

11 September 2018

Civil society groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

Gilead’s price gouging for sofosbuvir blocks millions of people from getting treatment

Tags Hepatitis C hepatitis C sofosbuvir generic medicinesintellectual property & trade

Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Outside Ministry of Commerce, Udyog Bhawan, New Delhi

Press release |

20 July 2018

ASEAN and India urged not to trade away people’s lives in trade agreement

RCEP trade deal could cut medicines lifeline for people in developing countries

Tags Intellectual property and trade hepatitis Ctuberculosis data exclusivitygeneric medicinesRegional Comprehensive Economic Partnership (RCEP)

97% of the medicines MSF uses to treat people with HIV are generics made in India.

Infographic

MSF and generic medicines

Tags Intellectual property and trade drug-resistant TBHIV/AIDS free trade agreementgeneric medicinesRegional Comprehensive Economic Partnership (RCEP)

Issue brief |

30 October 2017

Hepatitis C - Not even close

This issue brief provides information on currently available hepatitis C diagnostics and treatments, including pricing and registration information from manufacturers of direct-acting antivirals (DAAs). Reasons underlying the continued ...

Tags Hepatitis C hepatitis C sofosbuvirdaclatasvir generic medicines

Press release |

21 July 2017

RCEP negotiators must fix the damaging provisions that remain a threat to public health

As negotiators for the Regional Comprehensive Economic Partnership (RCEP) trade agreement meet for another round of negotiations in Hyderabad next week, networks of people living with HIV/AIDS from different parts of the country ...

Tags Intellectual property and trade data exclusivitygeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) India

Press release |

26 June 2017

MSF urges India’s Modi to remain committed to affordable medicines during White House meeting

Tags Intellectual property and trade access to medicinesgeneric medicines #HandsOffOurMeds India

Counting of medication Co-Trimoxizole at the HIV clinic at Madi Opei health centre, Kitgum District, Uganda, November 3, 2009.

Opinion article |

10 April 2017

What Japanese government can and should do for the affordable medicines in the world

Japan, China, South Korea, India, Australia, and New Zealand together with the 10 ASEAN countries, which comprise the Regional Comprehensive Economic Partnership (RCEP), are meeting in Kobe this week to continue trade negotiations that ...

Tags Intellectual property and trade access to medicinesgeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP)

Nearly 2,000 People Living With HIV along with MSF & other civil society organisations rallied in the streets of New Delhi at the start of the EU-India summit. They warned that harmful provisions in a trade deal being negotiated between the EU and India could severely hinder access to affordable medicine for people in developing countries.

Press release |

22 March 2017

India–EFTA trade talks may make medicines more expensive

Tags Intellectual property and trade access to medicinesgeneric medicinesintellectual property & trade European Free Trade Association #HandsOffOurMeds India

Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines during the 6th round of negotiations. 3rd December 2014

Opinion article |

08 March 2017

Don’t shut down the pharmacy of the developing world

Shailly Gupta, Deputy Head, MSF Access Campaign (India) emphaises the need to ensure availability of affordable medicines within public health programmes, which is the need of the hour

Tags Intellectual property and trade access to medicinesgeneric medicinesRegional Comprehensive Economic Partnership (RCEP) India

Letter |

24 February 2017

RCEP investment chapter presents a grave threat to access to medicines

Tags Intellectual property and trade access to medicinesgeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP)

Press release |

23 February 2017

MSF calls on Japan and South Korea to drop the harmful RCEP measures

Tags Intellectual property and trade access to medicinesdata exclusivitygeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) Japan

Celumusa Hlatswako, an MSF mobile counselor, visits Winile, 39, XDR-TB patient & HIV-positive. They use sign language to communicate because Winile went deaf due to the side effects of the treatment. Matsapha airport, Manzini Region, Swaziland.

Press release |

05 December 2016

RCEP trade deal negotiators must reject terms that would harm access to medicines

As negotiators from the 16 countries in the Regional Comprehensive Economic Partnership (RCEP) meet in Tangerang, Indonesia, starting today, international medical humanitarian organisation Médecins Sans Frontières (MSF), along with ...

Tags Intellectual property and trade generic medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP)Trans-Pacific Partnership Agreement (TPP)

Civil society demonstration against IP provisions in RCEP that can block access to affordable medicines. Protest was done during 6th RCEP negotiationin India, 2014.

Opinion article |

02 December 2016

On World AIDS Day, threat to access to medicines looms large

Today millions of people living with HIV in South-East Asia are receiving treatment and leading healthy lives thanks to affordable generic antiretroviral (ARVs) medicines.

Tags Intellectual property and trade HIV/AIDStuberculosis access to medicinesgeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) World AIDS Day ASEAN

Technical brief |

30 November 2016

RCEP IP chapter analysis

Tags access to medicinesgeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP)

Opinion article |

10 October 2016

The AIDS revolution is why ASEAN, India and China must resist controls on generic drugs

Dr Maria Guevara says affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia

Tags Intellectual property and trade access to medicinesgeneric medicinesintellectual property & tradeRegional Comprehensive Economic Partnership (RCEP) ASEAN

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Making the Switch

MSF update on 26th round of RCEP negotiations in Melbourne, Australia

Tribute to Dr Amit Sengupta

DR-TB Drugs Under the Microscope, 5th Edition

MSF response to ruling in Gilead sofosbuvir patent hearing at European Patent Office

Civil society groups call for end to Gilead’s unwarranted hepatitis C drug monopoly in Europe

ASEAN and India urged not to trade away people’s lives in trade agreement

MSF and generic medicines

Hepatitis C - Not even close

RCEP negotiators must fix the damaging provisions that remain a threat to public health

MSF urges India’s Modi to remain committed to affordable medicines during White House meeting

What Japanese government can and should do for the affordable medicines in the world

India–EFTA trade talks may make medicines more expensive

Don’t shut down the pharmacy of the developing world

RCEP investment chapter presents a grave threat to access to medicines

MSF calls on Japan and South Korea to drop the harmful RCEP measures

RCEP trade deal negotiators must reject terms that would harm access to medicines

On World AIDS Day, threat to access to medicines looms large

RCEP IP chapter analysis

The AIDS revolution is why ASEAN, India and China must resist controls on generic drugs